Malcolm Kenneth Robinson, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Bariatric Surgery | 13 | 2024 | 992 | 2.270 |
Why?
|
Obesity, Morbid | 17 | 2024 | 1277 | 1.980 |
Why?
|
Gastric Bypass | 10 | 2023 | 818 | 1.770 |
Why?
|
Malnutrition | 8 | 2024 | 645 | 1.480 |
Why?
|
Nutritional Status | 9 | 2024 | 1615 | 1.250 |
Why?
|
Obesity | 15 | 2024 | 12947 | 0.980 |
Why?
|
Monoamine Oxidase Inhibitors | 1 | 2023 | 156 | 0.880 |
Why?
|
Critical Illness | 7 | 2018 | 2723 | 0.870 |
Why?
|
Nutritional Support | 2 | 2018 | 173 | 0.810 |
Why?
|
Micronutrients | 1 | 2024 | 382 | 0.770 |
Why?
|
Gastroplasty | 4 | 2016 | 157 | 0.750 |
Why?
|
Ghrelin | 4 | 2013 | 252 | 0.730 |
Why?
|
Nutrition Therapy | 1 | 2020 | 102 | 0.630 |
Why?
|
Osteoarthritis | 1 | 2021 | 1063 | 0.440 |
Why?
|
Energy Intake | 2 | 2024 | 2134 | 0.420 |
Why?
|
S Phase | 1 | 2013 | 421 | 0.410 |
Why?
|
G1 Phase | 1 | 2013 | 403 | 0.410 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 473 | 0.400 |
Why?
|
Parenteral Nutrition | 2 | 2015 | 659 | 0.400 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 477 | 0.400 |
Why?
|
Laparoscopy | 4 | 2022 | 2036 | 0.380 |
Why?
|
Depressive Disorder | 1 | 2023 | 3728 | 0.360 |
Why?
|
Nutrition Assessment | 2 | 2024 | 728 | 0.360 |
Why?
|
Abdominal Pain | 1 | 2016 | 1071 | 0.340 |
Why?
|
Gastrectomy | 5 | 2023 | 672 | 0.330 |
Why?
|
Enteral Nutrition | 1 | 2015 | 794 | 0.320 |
Why?
|
Catheterization, Central Venous | 3 | 2013 | 526 | 0.310 |
Why?
|
Weight Loss | 9 | 2023 | 2684 | 0.310 |
Why?
|
Transcriptional Activation | 1 | 2013 | 1756 | 0.290 |
Why?
|
Hernia, Abdominal | 1 | 2007 | 56 | 0.270 |
Why?
|
MAP Kinase Signaling System | 1 | 2013 | 1486 | 0.270 |
Why?
|
Intestinal Fistula | 1 | 2007 | 142 | 0.260 |
Why?
|
Hospitals | 1 | 2019 | 3883 | 0.260 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2013 | 2457 | 0.240 |
Why?
|
Tyramine | 1 | 2023 | 53 | 0.230 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2013 | 2865 | 0.230 |
Why?
|
Selegiline | 1 | 2023 | 32 | 0.230 |
Why?
|
North America | 2 | 2024 | 1276 | 0.210 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 3206 | 0.210 |
Why?
|
Hernia, Hiatal | 2 | 2016 | 90 | 0.210 |
Why?
|
Intestinal Mucosa | 1 | 2013 | 3032 | 0.210 |
Why?
|
Osteoarthritis, Knee | 2 | 2023 | 1234 | 0.200 |
Why?
|
Critical Care | 1 | 2015 | 2697 | 0.200 |
Why?
|
Anastomotic Leak | 1 | 2023 | 163 | 0.200 |
Why?
|
Digestive System Surgical Procedures | 1 | 2007 | 572 | 0.190 |
Why?
|
Epithelial Cells | 1 | 2013 | 3677 | 0.190 |
Why?
|
Calciphylaxis | 1 | 2023 | 130 | 0.190 |
Why?
|
Intestine, Small | 1 | 2007 | 1206 | 0.180 |
Why?
|
Intensive Care Units | 4 | 2018 | 3744 | 0.180 |
Why?
|
Hypercalcemia | 1 | 2023 | 423 | 0.180 |
Why?
|
Tyrosine | 1 | 2023 | 1440 | 0.160 |
Why?
|
Humans | 43 | 2024 | 761596 | 0.160 |
Why?
|
Cost-Benefit Analysis | 4 | 2023 | 5493 | 0.150 |
Why?
|
Postoperative Complications | 3 | 2024 | 15633 | 0.140 |
Why?
|
Patient Care Team | 3 | 2009 | 2521 | 0.130 |
Why?
|
Patient Admission | 1 | 2003 | 1367 | 0.130 |
Why?
|
Spain | 1 | 2017 | 487 | 0.130 |
Why?
|
Menstruation Disturbances | 1 | 2016 | 143 | 0.120 |
Why?
|
Nutritional Requirements | 2 | 2015 | 276 | 0.120 |
Why?
|
Body Mass Index | 4 | 2019 | 12953 | 0.120 |
Why?
|
Calorimetry, Indirect | 1 | 2015 | 174 | 0.120 |
Why?
|
Female | 24 | 2024 | 392705 | 0.110 |
Why?
|
Retrospective Studies | 11 | 2024 | 80647 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 2 | 2016 | 20568 | 0.110 |
Why?
|
Communication Barriers | 1 | 2017 | 414 | 0.110 |
Why?
|
Infection Control | 1 | 2020 | 982 | 0.110 |
Why?
|
Caco-2 Cells | 1 | 2013 | 364 | 0.110 |
Why?
|
Gastroesophageal Reflux | 3 | 2016 | 819 | 0.110 |
Why?
|
Patient Discharge | 2 | 2024 | 3443 | 0.100 |
Why?
|
Macrophages | 1 | 2007 | 5767 | 0.100 |
Why?
|
Cytokines | 1 | 2007 | 7396 | 0.100 |
Why?
|
Databases, Factual | 2 | 2019 | 7968 | 0.100 |
Why?
|
Male | 21 | 2024 | 360846 | 0.100 |
Why?
|
Boston | 4 | 2017 | 9327 | 0.100 |
Why?
|
Ultrasonography | 1 | 2005 | 5971 | 0.100 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2023 | 1393 | 0.100 |
Why?
|
Vitamins | 1 | 2020 | 1635 | 0.100 |
Why?
|
Data Interpretation, Statistical | 1 | 2021 | 2691 | 0.090 |
Why?
|
Thinness | 1 | 2015 | 490 | 0.090 |
Why?
|
Intussusception | 1 | 2012 | 115 | 0.090 |
Why?
|
Patient Education as Topic | 3 | 2017 | 2319 | 0.090 |
Why?
|
Quality of Health Care | 1 | 2005 | 4331 | 0.090 |
Why?
|
Rest | 1 | 2015 | 918 | 0.090 |
Why?
|
Catheter-Related Infections | 1 | 2013 | 273 | 0.090 |
Why?
|
Pharmaceutical Services | 1 | 2011 | 141 | 0.090 |
Why?
|
Diet | 2 | 2024 | 8075 | 0.080 |
Why?
|
Infertility | 1 | 2016 | 654 | 0.080 |
Why?
|
Adult | 17 | 2024 | 221210 | 0.080 |
Why?
|
Catheterization, Peripheral | 1 | 2013 | 343 | 0.080 |
Why?
|
Metabolome | 1 | 2016 | 989 | 0.080 |
Why?
|
Treatment Outcome | 7 | 2023 | 64685 | 0.080 |
Why?
|
Survivors | 2 | 2017 | 2371 | 0.080 |
Why?
|
Blood Pressure | 1 | 2023 | 8481 | 0.070 |
Why?
|
Satiety Response | 1 | 2007 | 47 | 0.070 |
Why?
|
Signal Transduction | 2 | 2007 | 23447 | 0.070 |
Why?
|
Mass Screening | 1 | 2003 | 5429 | 0.070 |
Why?
|
Language | 1 | 2017 | 1543 | 0.070 |
Why?
|
Dietary Supplements | 1 | 2020 | 3415 | 0.070 |
Why?
|
Peptide YY | 1 | 2007 | 136 | 0.070 |
Why?
|
Middle Aged | 15 | 2024 | 220921 | 0.070 |
Why?
|
Transcription Factor RelA | 1 | 2007 | 254 | 0.070 |
Why?
|
Reimbursement Mechanisms | 2 | 2009 | 667 | 0.070 |
Why?
|
Health Services Accessibility | 2 | 2017 | 5440 | 0.060 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2007 | 687 | 0.060 |
Why?
|
Cohort Studies | 3 | 2023 | 41495 | 0.060 |
Why?
|
Radiology, Interventional | 1 | 2008 | 476 | 0.060 |
Why?
|
Aged | 8 | 2023 | 169310 | 0.060 |
Why?
|
Energy Metabolism | 1 | 2015 | 2882 | 0.060 |
Why?
|
Retinol-Binding Proteins | 1 | 2003 | 67 | 0.060 |
Why?
|
Perioperative Care | 1 | 2011 | 1036 | 0.060 |
Why?
|
Overweight | 1 | 2015 | 2417 | 0.050 |
Why?
|
Pilot Projects | 1 | 2017 | 8633 | 0.050 |
Why?
|
Follow-Up Studies | 4 | 2016 | 39106 | 0.050 |
Why?
|
Glucagonoma | 1 | 2002 | 14 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2013 | 10766 | 0.050 |
Why?
|
Risk Factors | 7 | 2024 | 74213 | 0.050 |
Why?
|
Societies, Medical | 1 | 2015 | 3905 | 0.050 |
Why?
|
Propensity Score | 2 | 2024 | 1913 | 0.050 |
Why?
|
Peptide Hormones | 1 | 2003 | 132 | 0.050 |
Why?
|
Phosphorylation | 1 | 2013 | 8321 | 0.050 |
Why?
|
Glutamine | 1 | 2005 | 577 | 0.050 |
Why?
|
United States | 5 | 2020 | 72340 | 0.050 |
Why?
|
Interleukin-10 | 1 | 2007 | 1175 | 0.050 |
Why?
|
Hypothalamus | 1 | 2007 | 999 | 0.050 |
Why?
|
Short Bowel Syndrome | 1 | 2005 | 353 | 0.050 |
Why?
|
Prealbumin | 1 | 2003 | 222 | 0.050 |
Why?
|
Interleukin-1beta | 1 | 2007 | 999 | 0.050 |
Why?
|
Erythema | 1 | 2002 | 262 | 0.050 |
Why?
|
Human Growth Hormone | 1 | 2005 | 642 | 0.040 |
Why?
|
Serum Albumin | 1 | 2003 | 672 | 0.040 |
Why?
|
Pharynx | 1 | 2003 | 432 | 0.040 |
Why?
|
Prospective Studies | 7 | 2016 | 54423 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2015 | 15266 | 0.040 |
Why?
|
Lipopolysaccharides | 1 | 2007 | 2206 | 0.040 |
Why?
|
Venous Thromboembolism | 1 | 2013 | 1866 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2015 | 14665 | 0.040 |
Why?
|
Costs and Cost Analysis | 1 | 2005 | 1668 | 0.040 |
Why?
|
Pregnancy Complications | 1 | 2013 | 2947 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2011 | 3600 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2016 | 22176 | 0.040 |
Why?
|
Quality Assurance, Health Care | 1 | 2008 | 2169 | 0.040 |
Why?
|
Patient Selection | 3 | 2020 | 4244 | 0.040 |
Why?
|
Reoperation | 3 | 2012 | 4303 | 0.040 |
Why?
|
Wasting Syndrome | 1 | 2017 | 99 | 0.040 |
Why?
|
Ambulatory Care | 1 | 2008 | 2775 | 0.040 |
Why?
|
Hypoxanthine | 1 | 2016 | 28 | 0.030 |
Why?
|
Amino Acids | 1 | 2002 | 1718 | 0.030 |
Why?
|
Pyrrolidonecarboxylic Acid | 1 | 2016 | 65 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2007 | 4352 | 0.030 |
Why?
|
Algorithms | 1 | 2016 | 14033 | 0.030 |
Why?
|
Antacids | 1 | 2016 | 94 | 0.030 |
Why?
|
Sleep Apnea, Obstructive | 2 | 2012 | 1875 | 0.030 |
Why?
|
Pancreatic Neoplasms | 2 | 2003 | 5368 | 0.030 |
Why?
|
Glutamates | 1 | 2016 | 389 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2007 | 5112 | 0.030 |
Why?
|
Warfarin | 1 | 2023 | 1483 | 0.030 |
Why?
|
Fatty Acids | 1 | 2002 | 1808 | 0.030 |
Why?
|
Glutathione | 1 | 2016 | 583 | 0.030 |
Why?
|
Renal Dialysis | 1 | 2023 | 1796 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2016 | 4853 | 0.030 |
Why?
|
Phlebitis | 1 | 2013 | 35 | 0.030 |
Why?
|
Purines | 1 | 2016 | 607 | 0.030 |
Why?
|
Evidence-Based Medicine | 3 | 2009 | 3688 | 0.030 |
Why?
|
Parenteral Nutrition, Total | 1 | 2013 | 304 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2007 | 18966 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2003 | 3826 | 0.020 |
Why?
|
Bariatric Medicine | 1 | 2011 | 12 | 0.020 |
Why?
|
Rats | 1 | 2007 | 23741 | 0.020 |
Why?
|
Infusions, Intravenous | 2 | 2008 | 2217 | 0.020 |
Why?
|
Sex Factors | 2 | 2015 | 10554 | 0.020 |
Why?
|
Jejunum | 1 | 2012 | 472 | 0.020 |
Why?
|
Length of Stay | 1 | 2003 | 6426 | 0.020 |
Why?
|
Comorbidity | 2 | 2015 | 10508 | 0.020 |
Why?
|
Logistic Models | 1 | 2003 | 13255 | 0.020 |
Why?
|
Incidence | 3 | 2013 | 21355 | 0.020 |
Why?
|
Birth Weight | 1 | 2016 | 2103 | 0.020 |
Why?
|
Time Factors | 2 | 2007 | 39969 | 0.020 |
Why?
|
Hyperlipidemias | 1 | 2012 | 771 | 0.020 |
Why?
|
Pregnancy | 3 | 2016 | 29890 | 0.020 |
Why?
|
Severity of Illness Index | 3 | 2015 | 15843 | 0.020 |
Why?
|
Canada | 1 | 2012 | 2122 | 0.020 |
Why?
|
Medically Underserved Area | 1 | 2009 | 254 | 0.020 |
Why?
|
Health Policy | 2 | 2009 | 2684 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2003 | 6345 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2012 | 14608 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2016 | 2922 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2011 | 931 | 0.020 |
Why?
|
Animals | 2 | 2007 | 168475 | 0.020 |
Why?
|
Odds Ratio | 1 | 2017 | 9647 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2008 | 13642 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2015 | 2759 | 0.020 |
Why?
|
Equipment Design | 1 | 2012 | 3511 | 0.010 |
Why?
|
Cooperative Behavior | 1 | 2011 | 1505 | 0.010 |
Why?
|
Injections, Subcutaneous | 1 | 2005 | 681 | 0.010 |
Why?
|
Specialization | 1 | 2009 | 778 | 0.010 |
Why?
|
Sepsis | 1 | 2017 | 2585 | 0.010 |
Why?
|
Patient Readmission | 1 | 2017 | 3271 | 0.010 |
Why?
|
Food Hypersensitivity | 1 | 2011 | 729 | 0.010 |
Why?
|
Prosthesis Failure | 1 | 2008 | 1204 | 0.010 |
Why?
|
Cachexia | 1 | 2003 | 202 | 0.010 |
Why?
|
Androstadienes | 1 | 2003 | 348 | 0.010 |
Why?
|
Mice | 1 | 2007 | 81539 | 0.010 |
Why?
|
Medicine | 1 | 2009 | 942 | 0.010 |
Why?
|
Probability | 1 | 2005 | 2477 | 0.010 |
Why?
|
Preoperative Care | 1 | 2009 | 2242 | 0.010 |
Why?
|
Neoplasms | 1 | 2008 | 22173 | 0.010 |
Why?
|
Age Factors | 1 | 2015 | 18399 | 0.010 |
Why?
|
Respiratory Function Tests | 1 | 2003 | 1682 | 0.010 |
Why?
|
Electromyography | 1 | 2003 | 1394 | 0.010 |
Why?
|
Administration, Oral | 1 | 2005 | 4021 | 0.010 |
Why?
|
Prognosis | 1 | 2017 | 29629 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2005 | 6228 | 0.010 |
Why?
|
Syndrome | 1 | 2002 | 3267 | 0.010 |
Why?
|
Polysomnography | 1 | 2003 | 1848 | 0.010 |
Why?
|
Cell Division | 1 | 2003 | 4465 | 0.010 |
Why?
|
Massachusetts | 1 | 2009 | 8833 | 0.010 |
Why?
|
Risk Assessment | 2 | 2009 | 23996 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2003 | 6131 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 26129 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2003 | 3597 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2013 | 7406 | 0.010 |
Why?
|
Coronary Disease | 1 | 2009 | 5914 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2005 | 8527 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2009 | 8002 | 0.010 |
Why?
|
Hypertension | 1 | 2012 | 8540 | 0.010 |
Why?
|
Prevalence | 1 | 2009 | 15733 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2009 | 7391 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2005 | 12341 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2009 | 20100 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2015 | 58984 | 0.010 |
Why?
|
Young Adult | 1 | 2016 | 59260 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2012 | 12149 | 0.000 |
Why?
|
Palliative Care | 1 | 2002 | 3598 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 2009 | 15502 | 0.000 |
Why?
|